Nipro Corporation logo

Nipro Corporation

8086.T

JPXHealthcareMedical - Instruments & Supplies

Latest quote

¥1,590.5

+¥4.50 · +0.28%

Aug 24, 3:30 PM JST

8086.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
JP
CEO
Yoshihiko Sano
Listed since
Jan 1, 2001
Employees
38,593

Market position

Volume
0
0× average
Average volume
706.5K
Average daily volume
Market cap
259.4B JPY
Beta
-0.01
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
793.6B JPY
P/E (TTM)
18.45×
P/B (TTM)
0.92×
P/S (TTM)
0.39×
EV / EBITDA
7.71×
Earnings yield
5.33%
Free cash flow yield
-3.03%
Dividend yield
1.82%

Profitability & efficiency

Gross margin
31.71%
Operating margin
5.70%
Net margin
2.10%
Return on equity
4.93%
Return on assets
1.11%
Return on invested capital
1.98%

Financial health

Debt / equity
2.34×
Current ratio
1.39×
Altman Z-score
1.12
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends35%22%10%-2%Gross margin, FY2021: 30.69%Gross margin, FY2022: 30.43%Gross margin, FY2023: 29.65%Gross margin, FY2024: 30.04%Gross margin, FY2025: 31.53%Operating margin, FY2021: 4.83%Operating margin, FY2022: 3.25%Operating margin, FY2023: 3.81%Operating margin, FY2024: 4.13%Operating margin, FY2025: 5.70%Net margin, FY2021: 2.72%Net margin, FY2022: 0.84%Net margin, FY2023: 1.89%Net margin, FY2024: 0.79%Net margin, FY2025: 2.04%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 30.69%. Gross margin FY2022 30.43%. Gross margin FY2023 29.65%. Gross margin FY2024 30.04%. Gross margin FY2025 31.53%. Operating margin FY2021 4.83%. Operating margin FY2022 3.25%. Operating margin FY2023 3.81%. Operating margin FY2024 4.13%. Operating margin FY2025 5.70%. Net margin FY2021 2.72%. Net margin FY2022 0.84%. Net margin FY2023 1.89%. Net margin FY2024 0.79%. Net margin FY2025 2.04%.

Income trends

Revenue

660.54B JPY+2.47%

Operating income

37.63B JPY+41.45%

Net income

13.5B JPY+164.06%
Income trends across reported periods726.13B JPY463.75B JPY201.36B JPY−61.02B JPYRevenue, FY2021: 494.79B JPYRevenue, FY2022: 545.2B JPYRevenue, FY2023: 586.79B JPYRevenue, FY2024: 644.59B JPYRevenue, FY2025: 660.54B JPYOperating income, FY2021: 23.88B JPYOperating income, FY2022: 17.73B JPYOperating income, FY2023: 22.34B JPYOperating income, FY2024: 26.6B JPYOperating income, FY2025: 37.63B JPYNet income, FY2021: 13.46B JPYNet income, FY2022: 4.58B JPYNet income, FY2023: 11.11B JPYNet income, FY2024: 5.11B JPYNet income, FY2025: 13.5B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 494.79B JPY. Revenue FY2022 545.2B JPY. Revenue FY2023 586.79B JPY. Revenue FY2024 644.59B JPY. Revenue FY2025 660.54B JPY. Operating income FY2021 23.88B JPY. Operating income FY2022 17.73B JPY. Operating income FY2023 22.34B JPY. Operating income FY2024 26.6B JPY. Operating income FY2025 37.63B JPY. Net income FY2021 13.46B JPY. Net income FY2022 4.58B JPY. Net income FY2023 11.11B JPY. Net income FY2024 5.11B JPY. Net income FY2025 13.5B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue660.54B JPY644.59B JPY586.79B JPY545.2B JPY494.79B JPY
Cost of goods sold452.26B JPY450.93B JPY412.81B JPY379.3B JPY342.95B JPY
Gross profit208.28B JPY193.66B JPY173.98B JPY165.9B JPY151.84B JPY
Research and development21.67B JPY20.85B JPY19.67B JPY18.73B JPY
Selling, general, and administrative170.66B JPY145.39B JPY130.8B JPY128.5B JPY109.22B JPY
Operating expenses170.66B JPY167.06B JPY151.64B JPY148.17B JPY127.95B JPY
Interest income2.21B JPY2.18B JPY1.58B JPY1.1B JPY669M JPY
Interest expense9.77B JPY7.84B JPY6.53B JPY4.5B JPY4.19B JPY
Depreciation and amortization63.74B JPY65.65B JPY58.87B JPY48.74B JPY46.16B JPY
Operating income37.63B JPY26.6B JPY22.34B JPY17.73B JPY23.88B JPY
Net income13.5B JPY5.11B JPY11.11B JPY4.58B JPY13.46B JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-15.08%
11 comparable reports
Latest EPS result
23.48
Estimate 14.17 · Beat by 65.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates72.9439.846.75-26.35Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 39.64, estimate 26.25, surprise +51.01%, Beat. Q2 2025, reported May 12, 2025: actual -9.07, estimate 51.58, surprise -117.58%, Miss. Q3 2025, reported Aug 8, 2025: actual 20.06, estimate 13.15, surprise +52.55%, Beat. Q4 2025, reported Nov 10, 2025: actual 16.15, estimate 8.19, surprise +97.19%, Beat. Q1 2026, reported Feb 9, 2026: actual 66.09, estimate 30.3, surprise +118.12%, Beat. Q2 2026, reported May 12, 2026: actual -19.5, estimate -16.01, surprise -21.77%, Miss. Q3 2026, reported Aug 10, 2026: actual 23.48, estimate 14.17, surprise +65.70%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 20.33, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates181.74B170.35B158.97B147.58BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 7, 2025: actual 167.27B JPY, estimate 163.96B JPY, surprise +2.02%, Beat. Q2 2025, reported May 12, 2025: actual 165.3B JPY, estimate 154.57B JPY, surprise +6.95%, Beat. Q3 2025, reported Aug 8, 2025: actual 159.22B JPY, estimate 158.89B JPY, surprise +0.21%, Beat. Q4 2025, reported Nov 10, 2025: actual 158.16B JPY, estimate 165.95B JPY, surprise -4.69%, Miss. Q1 2026, reported Feb 9, 2026: actual 169.92B JPY, estimate 174.75B JPY, surprise -2.76%, Miss. Q2 2026, reported May 12, 2026: actual 173.23B JPY, estimate 169.96B JPY, surprise +1.93%, Beat. Q3 2026, reported Aug 10, 2026: actual 167.55B JPY, estimate 166.7B JPY, surprise +0.51%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 168.39B JPY, surprise —, Comparison unavailable.

8086.T peers

ETFs holding 8086.T

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 8086.T

research.disclaimer